About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

DP-R212 Pharmacokinetic Study

NCT02789475·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Chul woo Kim, Ph.D.
CONTACT
82-92-890-1168 cwkim1805@inha.ac.kr

Lead

Alvogen Korea

Age

19–45

Sex

MALE

Healthy volunteers

Accepted

You may be eligible if

BMI 18-29
signed the informed consent form prior to the study participation

You may not be if

Clinically significant disease
Previously donate whole blood within 60 days or component blood within 14 days
Clinically significant allergic disease
Taken IP in other trial within 90 days
An impossible one who participates in clinical trial by investigator's decision including laboratory test result

The record

StatusUnknown

PhasePhase 1

Taking part38

StartedMay 2016

UpdatedJun 3, 2016

Conditions

Hypertension Hyperlipidemias

Where1

Inha university hospital
Jung-gu, Incheon, South Korea

Clareo Health | DP-R212 Pharmacokinetic Study